Perspective Therapeutics director granted 50K options

Williamson Robert F III reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Williamson Robert F III reported acquisition or exercise transactions in this Form 4 filing.

Perspective Therapeutics, Inc. director Robert F. Williamson III reported receiving a grant of stock options representing 50,000 shares on March 2, 2026. The award was approved by the board on January 26, 2026 as his annual equity grant for 2026 and will vest in full on March 2, 2027, provided he continues serving through that date.

Insider Trade Summary

Grant/Award: 50,000 shares

Grant/Award 1 txn

Insider Williamson Robert F III

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	50,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 50,000 contracts (Direct)

Footnotes (2)

1. F1. The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026.
2. F2. Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Perspective Therapeutics (CATX) report in this Form 4?

Perspective Therapeutics reported that director Robert F. Williamson III received a grant of stock options for 50,000 shares. The grant is characterized as his annual equity award for 2026 and was made effective on March 2, 2026, with specific vesting terms.

How many stock options did Robert F. Williamson III receive from Perspective Therapeutics (CATX)?

Robert F. Williamson III received stock options covering 50,000 shares of Perspective Therapeutics common stock. The Form 4 shows 50,000 derivative securities acquired in a single transaction, with 50,000 options reported as held following the grant, all as direct ownership.

When was the 2026 annual equity award for the Perspective Therapeutics (CATX) director approved and granted?

The annual equity award was approved by the board on January 26, 2026, with a grant date of March 2, 2026. These dates indicate when the company’s board authorized the option grant and when it was formally awarded to the reporting director.

What are the vesting terms of the 50,000 stock options granted by Perspective Therapeutics (CATX)?

The 50,000 stock options vest in full on March 2, 2027. Vesting is conditioned on the director’s continued service with the company through the vesting date, meaning the options become exercisable only if he remains in his role until then.

What role does the reporting person hold at Perspective Therapeutics (CATX)?

The reporting person, Robert F. Williamson III, is identified as a director of Perspective Therapeutics. The Form 4 indicates he is not an officer or ten percent owner, and the disclosed option grant represents his 2026 annual equity compensation as a board member.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 04:37 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Williamson Robert F III

(Last) (First) (Middle)

C/O PERSPECTIVE THERAPEUTICS, INC.

2401 ELLIOTT AVENUE, SUITE 320

(Street)

SEATTLE WA 98121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Perspective Therapeutics, Inc. [ CATX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$5.35	03/02/2026(1)		A		50,000		(2)	03/02/2036	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026.

2. Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date.

	/s/ Robert F. Williamson, III by Chris Nenno, as Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.